Relapse of systemic juvenile idiopathic arthritis after influenza vaccination in a patient receiving tocilizumab

Clin Vaccine Immunol. 2012 Oct;19(10):1700-2. doi: 10.1128/CVI.00309-12. Epub 2012 Aug 8.

Abstract

We report the case of a patient with systemic juvenile idiopathic arthritis (s-JIA) receiving tocilizumab (TCZ) who experienced relapses of s-JIA after receiving influenza vaccination. Systemic symptoms of s-JIA might be masked during TCZ therapy. Careful observation with the monitoring of serum interleukin (IL)-18 and IL-6 levels may be useful.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Arthritis, Juvenile* / drug therapy
  • Child, Preschool
  • Drug Interactions
  • Female
  • Humans
  • Influenza Vaccines / administration & dosage
  • Influenza Vaccines / adverse effects*
  • Interleukin-18 / blood
  • Interleukin-6 / blood
  • Recurrence
  • Vaccination

Substances

  • Antibodies, Monoclonal, Humanized
  • Influenza Vaccines
  • Interleukin-18
  • Interleukin-6
  • tocilizumab

Supplementary concepts

  • Rheumatoid Arthritis, Systemic Juvenile